Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.
Fox Chase Cancer Center | Strategic Alliance Partners
Latest from Fox Chase Cancer Center
Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the toxicity profile of bevacizumab when used to treat patients with ovarian cancer.
At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia
Robert A. Burger, MD, FACOG, FACS, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.
Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes
Dr. Lori Goldstein from Fox Chase Cancer Center on the Fox Chase Breast Evaluation Center
Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer
Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design
Dr. Barbara Burtness from Fox Chase Cancer Center Discusses the Upcoming Head and Neck Cancer Symposium
Advertisement
Advertisement
Trending on OncLive
1
Generic Enzalutamide Tablets Granted Tentative FDA Approval for Prostate Cancer
2
The OncFive: Top Oncology Articles for the Week of 6/21
3
T-DXd Plus Pertuzumab Sets New Treatment and Research Standards in HER2+ Breast Cancer
4
Five Under 5: Top Oncology Videos for the Week of 6/21
5